Wells Fargo & Company Issues Positive Forecast for Heartflow (NASDAQ:HTFL) Stock Price

Heartflow (NASDAQ:HTFL) had its price objective upped by Wells Fargo & Company from $39.00 to $70.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective points to a potential upside of 40.05% from the stock’s previous close.

A number of other analysts also recently issued reports on the stock. Morgan Stanley raised their price target on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Heartflow in a report on Wednesday, November 4th. Benchmark reiterated a “buy” rating on shares of Heartflow in a report on Friday, August 14th. Canaccord Genuity Group increased their price objective on Heartflow from $56.00 to $69.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Robert W. Baird raised their target price on Heartflow from $56.00 to $68.00 and gave the stock an “outperform” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.12.

Heartflow Stock Performance

Shares of HTFL stock traded down $9.94 on Friday, hitting $49.98. 1,650,276 shares of the stock traded hands, compared to its average volume of 1,609,452. The firm’s 50-day moving average price is $51.93 and its two-hundred day moving average price is $35.14. The stock has a market capitalization of $4.35 billion, a PE ratio of -27.35 and a beta of 2.50. Heartflow has a twelve month low of $20.13 and a twelve month high of $60.65.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.15. The firm had revenue of $72.86 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. During the same quarter in the previous year, the business posted ($0.27) earnings per share. On average, equities research analysts anticipate that Heartflow will post -0.75 EPS for the current fiscal year.

Insider Buying and Selling at Heartflow

In other news, insider Campbell Rogers sold 23,933 shares of the company’s stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $55.01, for a total value of $1,316,554.33. Following the transaction, the insider directly owned 73,453 shares in the company, valued at approximately $4,040,649.53. This represents a 24.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Farquhar sold 38,900 shares of the stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $55.74, for a total transaction of $2,168,286.00. Following the transaction, the chief executive officer directly owned 251,983 shares of the company’s stock, valued at $14,045,532.42. The trade was a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 332,403 shares of company stock worth $16,602,786 over the last three months. Insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. XXEC Inc. acquired a new position in Heartflow in the 2nd quarter valued at about $2,524,764,000. Quantinno Capital Management LP purchased a new stake in Heartflow during the first quarter worth about $1,734,000. Sei Investments Co. lifted its position in shares of Heartflow by 342.5% during the first quarter. Sei Investments Co. now owns 67,048 shares of the company’s stock worth $1,631,000 after purchasing an additional 51,895 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Heartflow during the second quarter worth about $19,096,000. Finally, Handelsbanken Fonder AB purchased a new position in shares of Heartflow in the second quarter valued at approximately $910,000.

Top Heartflow Stories

Investors following HTFL have been watching these stories:

• Positive Sentiment: Q3 results beat expectations. HeartFlow reported revenue of $72.9 million, above the $65.2 million FactSet estimate, and a loss of $0.03 per share versus the consensus estimate of a $0.18 loss. The per-share loss also narrowed from $0.27 a year earlier. Zacks Q3 results article
• Positive Sentiment: 2026 revenue outlook rose above expectations. The company guided to $262 million–$264 million in revenue, versus analyst estimates around $248.5 million, signaling stronger expected growth. HeartFlow Q3 results and guidance
• Positive Sentiment: Analysts raised targets and maintained bullish ratings. Stifel lifted its target to $70 with a buy rating; Canaccord raised its target to $69 with a buy rating; and Baird increased its target to $68 with an outperform rating. These revisions reflect greater potential upside in analysts’ views.

Heartflow Company Profile

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.